Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL29874034 | 1.00 | ALDH1A1 (0.42) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| Lithium Ion SCHEMBL30033845 | 0.95 | ALDH1A1 (0.42) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| SCHEMBL141446 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| SCHEMBL8800602 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| Ethane SCHEMBL9181718 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| Ammonia Solution, Strong SCHEMBL28791130 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| SCHEMBL28186389 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| SCHEMBL5143571 | 0.77 | ALDH1A1 (0.48) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| SCHEMBL41804 | 0.75 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAHSD17B10ALOX15 | |
| SCHEMBL4112176 | 0.75 | ALDH1A1 (0.46) | ALDH1A1HPGDLMNAHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024206939-A2 | SARS-COV-2 ENTRY INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-3884939-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-4058446-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| EP-3884939-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3426243-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-1334976-A1 | Novel phosphine compound, transition metal complex containing said compound as ligand and asymetric synthesis catalyst containing said complex | Takasago International Corporation (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030144139-A1 | Novel phosphine compound, transition metal complex containing the same phosphine compound as ligand and asymmetric synthesis catalyst containing the complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-07-31 | — | — | US | disclosed |
| US-6548695-B2 | Immunoregulation | MERCIAN CORPORATION (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20020147350-A1 | Process for producing isocoumarins and intermediates for the same | TSUCHIDA TOSHIO (JP) | 2002-10-10 | — | — | US | disclosed |
| US-6426420-B1 | REACTING A HOMOPHTHALIC ACID DERIVATIVE WITH A MALONIC ACID DERIVATINE | MERCIAN CORPORATION (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1200421-A1 | PROCESS FOR PRODUCING ISOCOUMARINS AND INTERMEDIATES FOR THE SAME | MERCIAN CORPORATION (JP) | 2002-05-02 | — | — | EP | disclosed |
| EP-0749964-B1 | N-Heterocyclyl biphenyl sulfonamides | ASTRAZENECA AB (SE) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001007429-A1 | PROCESS FOR PRODUCING ISOCOUMARINS AND INTERMEDIATES FOR THE SAME | MERCIAN CORPORATION (JP) | 2001-02-01 | — | — | WO | disclosed |
| US-5668137-A | N-heterocyclic sulfonamides having endothelin receptor activity | ZENECA LTD. (GB) | 1997-09-16 | — | — | US | disclosed |
| EP-0749964-A1 | N-Heterocyclyl biphenyl sulfonamides | ZENECA LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | ALDH1A1 222/4885HPGD 97/4885LMNA 3385/4885 |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | ALDH1A1 2009/4885HPGD 599/4885LMNA 2772/4885 |
| US-20030144139-A1 | Novel phosphine compound, transition metal complex containing the same phosphine compound as ligand and asymmetric synthesis catalyst containing the complex | PHOSPHO1, MEN1, PDCD1 | ALDH1A1 4025/4885HPGD 3624/4885LMNA 4812/4885 |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | ALDH1A1 222/4885HPGD 97/4885LMNA 3385/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | ALDH1A1 222/4885HPGD 97/4885LMNA 3385/4885 |
| US-20020147350-A1 | Process for producing isocoumarins and intermediates for the same | IDH1, IDH2, ME1 | ALDH1A1 241/4885HPGD 161/4885LMNA 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.